Literature DB >> 9039656

Delivery of liposome-sequestered hydrophobic proteins to lysosomes of normal and Batten disease cells.

N H Ansari1, Q He, J D Cook, J Wen, S K Srivastava.   

Abstract

We have developed a method to deliver hydrophobic proteins such as ATP synthase subunit c and ubiquitin to lysosomes of PMN (polymorphonucleocytes) and fibroblasts. ATP synthase subunit c is stored in the lysosomes of various tissues in late infantile and juvenile forms of neuronal ceriod lipofuscinosis, also called Batten disease (BD). Whether this protein storage is due to an abbreviation in protein or in the lysosomal hydrolases of BD is still not clear. We have sequestered this protein and ubiquitin in the lipid membrane of liposomes. The liposomes coated with autologous heat-aggregated IgG or apolipoprotein E when presented to the PMN and fibroblasts, respectively, accumulated in the lysosomes. Both normal and BD PMN degraded 125I-ubiquitin; the rate of degradation was, however, slower by Batten PMN. These studies indicate that a hydrophobic molecule such as subunit c can be delivered to PMN and fibroblasts, and the sequestered proteins are accessible to lysosomal hydrolases. Therefore, this technique can be used to study the metabolism of highly hydrophobic proteins by lysosomes, especially the biochemical mechanism(s) of subunit c storage in BD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9039656     DOI: 10.1002/(sici)1097-4547(19970201)47:3<341::aid-jnr12>3.0.co;2-4

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  6 in total

Review 1.  New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010 Mar-Apr

2.  Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Drug Deliv Transl Res       Date:  2012-06-01       Impact factor: 4.617

3.  Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.

Authors:  Janet Hsu; Daniel Serrano; Tridib Bhowmick; Kishan Kumar; Yang Shen; Yuan Chia Kuo; Carmen Garnacho; Silvia Muro
Journal:  J Control Release       Date:  2010-11-01       Impact factor: 9.776

Review 4.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

Review 5.  Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis.

Authors:  Ryan D Geraets; Seung yon Koh; Michelle L Hastings; Tammy Kielian; David A Pearce; Jill M Weimer
Journal:  Orphanet J Rare Dis       Date:  2016-04-16       Impact factor: 4.123

Review 6.  CNS-Targeting Therapies for Lysosomal Storage Diseases: Current Advances and Challenges.

Authors:  Mariola J Edelmann; Gustavo H B Maegawa
Journal:  Front Mol Biosci       Date:  2020-11-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.